EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer

Yong Liu, Qiang Xue, Baogui Wang, Xuewei Ding, Rupeng Zhang, Xiaona Wang, Bin Ke, Xuejun Wang, Ning Liu, Jingyu Deng iD, Hongjie Zhan, Bin Li und 6 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35511 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Yong Liu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Pyridines, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tianjin Key Medical Discipline (Specialty) Construction Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In selected patients with stage IV gastric cancer, radical surgery after conversion therapy may increase survival benefit; however, there is currently no standard protocol for conversion therapy. We explored the feasibility and efficacy of sintilimab plus two‐drug chemotherapy (S‐1 plus nab‐paclitaxel) and apatinib as conversion therapy in patients with stage IV gastric cancer in China. This was a prospective, single‐arm, single‐center, phase 2 study. The primary endpoint was the R0 conversion rate, defined as the proportion of R0 surgical patients to the total number of patients treated. Of 56 patients screened, 47 were enrolled, received preoperative treatment, and were evaluated for tumor response. Most patients (28/47; 59.6%) had two or three unresectable factors. The objective response rate and disease control rate were 53.2% and 97.9%, respectively. Of the 46/47 patients who achieved disease control, 35 underwent surgery. The R0 conversion rate was 51.1% (24/47). A pathological complete response was observed in 14.3% (5/35) of patients. Median overall survival and event‐free survival were 25.7 and 15.3 months, respectively. Overall survival and event‐free survival were significantly better in surgical patients compared with non‐surgical patients ( p < 0.001). In the surgical population, R1/R2 resection was the only significant independent predictor of unfavorable event‐free survival by multivariate analysis ( p = 0.015). There were no chemotherapy‐ or perioperative‐related deaths. The safety profile was manageable. Sintilimab plus chemotherapy and apatinib followed by conversional resection may be a new feasible and safe option for initially unresectable gastric cancer, potentially leading to long‐term survival or even cure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsPyridinesAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAgedPaclitaxelAdultNeoplasm StagingProspective StudiesOxonic AcidTegafurDrug CombinationsAlbumins

Stichwörter der Autor:innen

apatinibconversion therapyprospective studysintilimabstage IV gastric cancer

Substanzen

apatinibPyridinesAntibodies, Monoclonal, HumanizedPaclitaxelsintilimabOxonic AcidTegafurS 1 (combination)130-nm albumin-bound paclitaxelDrug Combinations

Autor:innen und Institutionen

  • Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
  • Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, China.

ORCID-Profile: Jingyu Deng, Han Liang

Förderung

  • Tianjin Key Medical Discipline (Specialty) Construction Project

Zitieren

APA

Liu, Y., Xue, Q., Wang, B., Ding, X., Zhang, R., Wang, X., Ke, B., Wang, X., Liu, N., Deng, J., Zhan, H., Li, B., Wu, L., Cai, M., Zhang, L., Huang, W., Jin, P., & Liang, H. (2025). Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.35511

Vancouver

Liu Y, Xue Q, Wang B, Ding X, Zhang R, Wang X, et al. Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer. International Journal of Cancer. 2025. doi:10.1002/ijc.35511

BibTeX
@article{Liu2025,
  author = {Liu, Yong and Xue, Qiang and Wang, Baogui and Ding, Xuewei and Zhang, Rupeng and Wang, Xiaona and Ke, Bin and Wang, Xuejun and Liu, Ning and Deng, Jingyu and Zhan, Hongjie and Li, Bin and Wu, Liangliang and Cai, Mingzhi and Zhang, Li and Huang, Wenbai and Jin, Peng and Liang, Han},
  title = {Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35511}
}
Kostenlos starten →